Understanding JAK Inhibitors: Side Effects and Recommendations

The discussion centers on Janus kinase (JAK) inhibitors, focusing on their side effects, recommendations, and monitoring protocols. The speaker, a principal investigator for Pfizer, emphasizes a cautious approach to using JAK inhibitors, particularly in immunosuppressed patients. Side effects include infections, malignancies, and thrombotic effects, with particular attention to the data that led to black box warnings on these medications. The complexities of the JAK-STAT signaling pathway, which JAK inhibitors target, suggest potential unintended consequences when disrupted. The conversation highlights the need for vigilant lab monitoring and patient history assessments, including cardiovascular risks and possible GI perforation. Vaccination guidelines for immunosuppressed patients are provided, indicating which vaccines are recommended and when vaccinations should occur relative to starting medication. The speaker notes the importance of comprehensive patient education about the risks and benefits of JAK inhibitors, especially for those requiring long-term therapy. There are recommendations for screening patients before starting therapy, including recent studies suggesting increased risks of DVTs in certain populations. Overall, while JAK inhibitors are relatively new with promising benefits, the speaker advocates for ongoing research and careful patient management to mitigate risks.